Fine tuning cardiac ablation could lead to quicker results for patients with arrhythmias

University of Michigan chemists and physicians examine a new method for targeted cardiac ablation that could lead to quicker results for patients with arrhythmias. Credit: University of Michigan Health System

University of Michigan heart researchers are shedding light on a safer method for steadying an abnormal heart rhythm that prevents collateral damage to healthy cells.

, or arrhythmias, set the stage for a common, debilitating disorder called atrial fibrillation that puts adults as young as age 40 at risk for fatigue, fainting, cardiac arrest, and even death. Medications can help, but doctors also use catheter ablation in which are delivered to a region of the heart to disrupt the arrhythmia.

However, studies show half of patients require more than one ablation to see results. In a laboratory study, the U-M used photodynamic therapy, a technique long used in cancer research, to disrupt the specific cells causing the arrhythmia.

The study suggests cell-specific cardiac ablation could help patients avoid complications, and get closer to an arrhythmia-free life without having to undergo repeat hospital visits.

Chemists in the U-M Department of Chemistry and electrophysiologists at the U-M Center for Arrhythmia Research collaborated on the study that will require further examination before it is available in the hospital setting.

"This cell-selective therapy may represent an innovative concept to overcome some of the current limitations of cardiac ablation," says lead study author Uma Mahesh Avula, M.D., research fellow at the U-M Center for Research.

The study was published online ahead of print in the September issue of the Journal of Heart Rhythm.

The heart consists of different types of cells such as myocytes, fibroblast, adiopocytes and purkinje fibers, which are all needed for normal cardiac activity.

The new study is the first of its kind to use photodynamic therapy and nanotechnology to ablate only the responsible for arrhythmias. In current ablative techniques, all receive ablative energy, which can lead to complications such as puncturing the , bleeding or stroke.

"Current ablation techniques are severely limited by its non-specific nature of cellular damage. Besides this lack of cellular discrimination markedly increases the required energy amounts and prolongs procedure times, all of which reduces overall ablation results," Avula says.

has emerged as an important treatment option that requires careful assessment, planning and execution for optimal success rates. Advances over the past 20 years have made the treatment safer, but it remains highly complex.

"Approaches that could simplify and shorten the procedure may contribute to more patients being treated," Avula says.

Rather than radiofrequency energy, the most common type used in , the U-M team introduces the use of PDT in cardiac electrophysiology to target specific cell types. Targeted PDT, which was pioneered in the labs of study senior author U-M chemist and engineer Raoul Kopelman, Ph.D., is extensively used in cancer research for selectively killing cancerous cells.

The disruption induced by PDT is confined to cells that have been photosensitized, while adjacent non-photosensitized cells are unaffected.

"We think this approach will decrease the extent of unwanted cell injury, inflammation, and ablation-related tissue damage, and pave a way for the development of more effective therapies for cardiac arrhythmias," says study senior author Jérôme Kalifa, M.D., Ph.D., assistant professor of internal medicine at the U-M Health System.

More information: "Cell-specific nanoplatform-enabled photodynamic therapy for cardiac cells," Journal of Heart Rhythm, dx.doi.org/10.1016/j.hrthm.2012.05.011

Related Stories

UCSD uses heat energy to fix odd heart beat

date Feb 17, 2012

(Medical Xpress) -- UC San Diego Sulpizio Cardiovascular Center is now offering patients with atrial fibrillation the breakthrough benefits of heat energy, or radio frequency waves, to irreversibly alter heart ...

Recommended for you

1950s drug is future heart treatment

date May 22, 2015

Oxford University researchers have found a promising future treatment for heart disease, going back to a drug first developed in 1950.

Time is muscle in acute heart failure

date May 21, 2015

Urgent diagnosis and treatment in acute heart failure has been emphasised for the first time in joint recommendations published today in European Heart Journal.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

danwalter2012
Jul 24, 2012
Catheter ablation for afib is a corporate-driven procedure which is riskier and less effective than advertised: Google "Collateral Damage: A Patient, a New Procedure and the Learning Curve"

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.